FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754690494> ?p ?o ?g. }

• W2754690494 endingPage "828" @default.
• W2754690494 startingPage "818" @default.
• W2754690494 abstract "Andean bear (Tremarctos ornatus) alopecia syndrome (ABAS) commonly affects captive bears, particularly sexually mature females. ABAS is characterized by bilaterally symmetrical predominantly flank alopecia with or without profound pruritus and secondary bacterial and Malassezia infections. There is no effective treatment and severely affected bears have been euthanized. This paper describes the successful management of ABAS in three female Andean bears. Skin biopsies and cytology revealed a mixed dermal inflammatory infiltrate, alopecia, hyperkeratosis, and Malassezia dermatitis. Allergen specific serology was positive for environmental allergens in one case. Hematology, serum biochemistry, and thyroid and adrenal function were normal in all cases. There was no consistent response to novel diet trials, antifungals, antihistamines, allergen specific immunotherapy, or topical antimicrobials. There was a partial response to ciclosporin (Atopica® cat, Novartis Animal Health; 5 mg/kg po, sid) in one case and oral glucocorticoids in all cases (dexamethasone sodium phosphate, [Colvasone 0.2%, Norbrook], 0.15 mg/kg po, sid or prednisolone [Deltacortene, Bruno Farmaceutici, and Megasolone 20, Coophavet], 0.3–1.2 mg/kg po, sid), but treatment was withdrawn following adverse effects. Treatment with oclacitinib maleate (Apoquel®, Zoetis; 0.46–0.5 mg/kg po, bid) resulted in rapid and complete resolution of the pruritus with subsequent improvement in demeanor and fur regrowth. After 5 mo, the bears were almost fully furred and off all other medication. Treatment was tapered to the lowest dose that prevented relapse of the pruritus (0.23–0.4 mg/kg po, sid). No adverse effects have been noted. ABAS is usually an intractable condition, and, to our knowledge, oclacitinib is the first treatment shown to result in sustained clinical improvement. Further studies on the etiology of ABAS, and on efficacy and long-term safety of oclacitinib are needed." @default.
• W2754690494 created "2017-09-25" @default.
• W2754690494 creator A5000970902 @default.
• W2754690494 creator A5018591810 @default.
• W2754690494 creator A5027745507 @default.
• W2754690494 creator A5034677547 @default.
• W2754690494 creator A5058363285 @default.
• W2754690494 creator A5070385529 @default.
• W2754690494 creator A5072669757 @default.
• W2754690494 creator A5073039991 @default.
• W2754690494 creator A5076070228 @default.
• W2754690494 creator A5079578178 @default.
• W2754690494 creator A5079783800 @default.
• W2754690494 creator A5082800408 @default.
• W2754690494 creator A5090845341 @default.
• W2754690494 date "2017-09-01" @default.
• W2754690494 modified "2023-10-16" @default.
• W2754690494 title "TREATMENT SUCCESS IN THREE ANDEAN BEARS (TREMARCTOS ORNATUS) WITH ALOPECIA SYNDROME USING OCLACITINIB MALEATE (APOQUEL®)" @default.
• W2754690494 cites W1504621077 @default.
• W2754690494 cites W1946930161 @default.
• W2754690494 cites W1984317973 @default.
• W2754690494 cites W1985772597 @default.
• W2754690494 cites W1986178253 @default.
• W2754690494 cites W2051993308 @default.
• W2754690494 cites W2073393820 @default.
• W2754690494 cites W2081559924 @default.
• W2754690494 cites W2083245833 @default.
• W2754690494 cites W2095414365 @default.
• W2754690494 cites W2105110037 @default.
• W2754690494 cites W2294333737 @default.
• W2754690494 cites W2345166378 @default.
• W2754690494 cites W2420387358 @default.
• W2754690494 doi "https://doi.org/10.1638/2016-0239.1" @default.
• W2754690494 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28920784" @default.
• W2754690494 hasPublicationYear "2017" @default.
• W2754690494 type Work @default.
• W2754690494 sameAs 2754690494 @default.
• W2754690494 citedByCount "36" @default.
• W2754690494 countsByYear W27546904942019 @default.
• W2754690494 countsByYear W27546904942020 @default.
• W2754690494 countsByYear W27546904942021 @default.
• W2754690494 crossrefType "journal-article" @default.
• W2754690494 hasAuthorship W2754690494A5000970902 @default.
• W2754690494 hasAuthorship W2754690494A5018591810 @default.
• W2754690494 hasAuthorship W2754690494A5027745507 @default.
• W2754690494 hasAuthorship W2754690494A5034677547 @default.
• W2754690494 hasAuthorship W2754690494A5058363285 @default.
• W2754690494 hasAuthorship W2754690494A5070385529 @default.
• W2754690494 hasAuthorship W2754690494A5072669757 @default.
• W2754690494 hasAuthorship W2754690494A5073039991 @default.
• W2754690494 hasAuthorship W2754690494A5076070228 @default.
• W2754690494 hasAuthorship W2754690494A5079578178 @default.
• W2754690494 hasAuthorship W2754690494A5079783800 @default.
• W2754690494 hasAuthorship W2754690494A5082800408 @default.
• W2754690494 hasAuthorship W2754690494A5090845341 @default.
• W2754690494 hasConcept C126322002 @default.
• W2754690494 hasConcept C16005928 @default.
• W2754690494 hasConcept C197934379 @default.
• W2754690494 hasConcept C203014093 @default.
• W2754690494 hasConcept C207480886 @default.
• W2754690494 hasConcept C2776715498 @default.
• W2754690494 hasConcept C2777472678 @default.
• W2754690494 hasConcept C2778329239 @default.
• W2754690494 hasConcept C2779915019 @default.
• W2754690494 hasConcept C2780510475 @default.
• W2754690494 hasConcept C2780717550 @default.
• W2754690494 hasConcept C71924100 @default.
• W2754690494 hasConcept C90924648 @default.
• W2754690494 hasConceptScore W2754690494C126322002 @default.
• W2754690494 hasConceptScore W2754690494C16005928 @default.
• W2754690494 hasConceptScore W2754690494C197934379 @default.
• W2754690494 hasConceptScore W2754690494C203014093 @default.
• W2754690494 hasConceptScore W2754690494C207480886 @default.
• W2754690494 hasConceptScore W2754690494C2776715498 @default.
• W2754690494 hasConceptScore W2754690494C2777472678 @default.
• W2754690494 hasConceptScore W2754690494C2778329239 @default.
• W2754690494 hasConceptScore W2754690494C2779915019 @default.
• W2754690494 hasConceptScore W2754690494C2780510475 @default.
• W2754690494 hasConceptScore W2754690494C2780717550 @default.
• W2754690494 hasConceptScore W2754690494C71924100 @default.
• W2754690494 hasConceptScore W2754690494C90924648 @default.
• W2754690494 hasIssue "3" @default.
• W2754690494 hasLocation W27546904941 @default.
• W2754690494 hasLocation W27546904942 @default.
• W2754690494 hasOpenAccess W2754690494 @default.
• W2754690494 hasPrimaryLocation W27546904941 @default.
• W2754690494 hasRelatedWork W1989515154 @default.
• W2754690494 hasRelatedWork W2090311795 @default.
• W2754690494 hasRelatedWork W2408856304 @default.
• W2754690494 hasRelatedWork W2418641793 @default.
• W2754690494 hasRelatedWork W2473788747 @default.
• W2754690494 hasRelatedWork W2503273482 @default.
• W2754690494 hasRelatedWork W2822638964 @default.
• W2754690494 hasRelatedWork W3122519522 @default.
• W2754690494 hasRelatedWork W3134073578 @default.
• W2754690494 hasRelatedWork W4234329252 @default.
• W2754690494 hasVolume "48" @default.
• W2754690494 isParatext "false" @default.

• next